scieee Science in your language
[en] (orig)

Understanding Parkinson disease in Spain: Genetic and clinical insights

Abstract

Background and purpose: Parkinson disease (PD) is a complex and heterogeneous neurodegenerative disorder with a broad spectrum of clinical manifestations, determined by a complex interplay of environmental and genetic factors. This study aimed to investigate genetic variants associated with PD and assess their impact on the disease phenotype through genotype–phenotype correlations. Methods: We employed a targeted resequencing panel to analyze 27 genes linked to PD in a cohort of 1185 PD patients from southern Spain. Variants were categorized based on the American College of Medical Genetics and Genomics pathogenicity criteria. Demographic and clinical data were also collected. Results: Among the patients analyzed, 13.5% carried potential disease-causing pathogenic or likely pathogenic variants in 12 different genes, indicating significant genetic heterogeneity. The most frequently affected genes were LRRK2, PRKN, and GBA1 (accounting for 72.1% of positive cases). Sex-specific differences were observed, with a higher proportion of female patients carrying LRRK2 variants. Differences in age at onset and clinical features were also observed among the different mutated genes. Notably, variants in genes associated with atypical parkinsonism presented distinct clinical presentations, highlighting the importance of genetic factors in the differential diagnosis. Conclusions: Our study provides valuable information on the genetic landscape of PD and its clinical manifestations. The observed genotype–phenotype correlations, along with sex-specific differences, emphasize the complexity of PD pathogenesis, underlining the importance of personalized approaches to PD diagnosis and treatment. Further investigations into genetic interactions and population-specific effects are warranted to enhance our understanding of PD etiology and improve patient care.

Read accessible full text

Understanding Parkinson disease in Spain: Genetic and clinical insights

Author: Gómez Garre, Pilar; Martín Bornez, Miguel; Muñoz Delgado, Laura; Díaz-Belloso, Rafael; Periñán Tocino, María Teresa; Bonilla Toribio, Marta; García Díaz, Sergio; Carrillo García, Fátima María; Mir Rivera, Pablo
Publisher: Wiley
Year: 2025
DOI: 10.1111/ene.16499
Source: https://idus.us.es/bitstreams/08c1cf90-c169-4a78-9804-3ef1f9604b84/download
Eu J Neu ol. 2025;32:e16499.  
|
1 o 9
h ps://doi.o g/10.1111/ene.16499
wileyonlinelib a y.com/jou nal/ene
Recei ed:7May2024
|
Accep ed:16Sep embe 2024
DOI: 10.1111/ene.16499
ORIGINAL ARTICLE
Unde s anding Pa kinson disease in Spain: Gene ic and clinical
insigh s
Pila Gómez- Ga e1,2  | Miguel Ma ín- Bó nez1 | Lau a Muñoz- Delgado1,2 |
Ra ael Díaz- Belloso1,2,3  | Ma ía Te esa Pe iñán1,2,4 | Ma a Bonilla- To ibio1,2 |
Dolo es Buiza- Rueda1,2 | Daniel Macías- Ga cía1,2  | Sil ia Jesús1,2 |
As id Ada mes- Gómez1,2 | Elena Ojeda1,2 | An onio Luque- Amb osiani1 |
Se gio Ga cía- Díaz1 | Rocío Pineda Sánchez1,2 | Fá ima Ca illo1,2,3 | Pablo Mi 1,2,3
1UnidaddeT as o nosdelMo imien o,Se iciodeNeu ología,Ins i u odeBiomedicinadeSe illa,IBiS/Hospi alUni e si a ioVi gendelRocío/CSIC/
Uni e sidaddeSe illa,Se ille,Spain
2Cen odeIn es igaciónBiomédicaenRedsob eEn e medadesNeu odegene a i as,Ins i u odeSaludCa losIII,Mad id,Spain
3Depa amen odeMedicina,Facul addeMedicina,Uni e sidaddeSe illa,Se ille,Spain
4Cen e o P e en i eNeu ologyUni ,Wol sonIns i u eo Popula ionHeal h,QueenMa yUni e si yo London,London,UK
Thisisanopenaccessa icleunde  he e mso  heC ea i eCommonsA ibu ion-NonComme cialLicense,whichpe mi suse,dis ibu ionand ep oduc ion
inanymedium,p o ided heo iginalwo kisp ope lyci edandisno used o comme cialpu poses.
©2024TheAu ho (s).Eu opean Jou nal o Neu ologypublishedbyJohnWiley&SonsL donbehal o Eu opeanAcademyo Neu ology.
Co espondence
Pila Gómez-Ga eandPabloMi ,Unidad
de T as o nos del Mo imien o, Ins i u o
deBiomedicinadeSe illa(IBiS),Hospi al
Uni e si a ioVi gendelRocío/CSIC/
Uni e sidaddeSe illa,A anzadaManuel
Siu o s/n,Se ille41013,Spain.
Email:mgomez-[email p o ec ed] and pmi @us.es
Funding in o ma ion
Conseje íadeEconomía,Inno ación,
CienciayEmpleodelaJun adeAndalucía,
G an /Awa dNumbe :CTS-7685,CVI-
02526andPY20_00896;Conseje íade
SaludyBienes a SocialdelaJun ade
Andalucía,G an /Awa dNumbe :PE-
0 1 8 6 - 2 0 1 9 ,  P E - 0 2 1 0 - 2 0 1 8 ,  P I - 0 4 5 9 - 2 0 1 8 
andPI-0471-2013;G an /Awa dNumbe :
RTC2019-007150-1,Ins i u odeSalud
Ca losIII(ISCIII)andco- undedby he
Eu opeanUnion,G an /Awa dNumbe :
PI14/01823,PI16/01575,PI18/01898,
PI19/01576andPI21/01875
Abs ac
Backg ound and pu pose: Pa kinsondisease(PD)isacomplexandhe e ogeneousneu o-
degene a i ediso de wi hab oadspec umo clinicalmani es a ions,de e minedbya
complexin e playo en i onmen alandgene ic ac o s.Thiss udyaimed oin es iga e
gene ic a ian sassocia edwi hPDandassess hei impac on hediseasepheno ype
h ough geno ype–pheno ype co ela ions.
Me hods: Weemployeda a ge ed esequencingpanel oanalyze27geneslinked o
PD in a coho  o  1185 PD pa ien s om sou he n Spain. Va ian s we e ca ego ized
basedon heAme icanCollegeo MedicalGene icsandGenomicspa hogenici yc i e ia.
Demog aphic and clinical da a we e also collec ed.
Resul s: Among hepa ien sanalyzed,13.5%ca iedpo en ialdisease-causingpa ho-
genico likelypa hogenic a ian sin12di e en genes,indica ingsigni ican gene ic
he e ogenei y.Themos  equen lya ec edgeneswe eLRRK2, PRKN, and GBA1(ac-
coun ing o  72.1%o  posi i e cases).Sex-speci ic di e enceswe e obse ed, wi h a
highe p opo iono  emalepa ien sca yingLRRK2 a ian s.Di e encesinagea onse 
andclinical ea u eswe ealsoobse edamong hedi e en mu a edgenes.No ably,
a ian s in genes associa ed wi h a ypical pa kinsonism p esen ed dis inc clinical p esen-
a ions,highligh ing heimpo anceo gene ic ac o sin hedi e en ialdiagnosis.
Conclusions: Ou s udyp o ides aluablein o ma ionon hegene iclandscapeo PD
andi sclinicalmani es a ions.Theobse edgeno ype–pheno ypeco ela ions, along
wi hsex-speci icdi e ences,emphasize hecomplexi yo PDpa hogenesis,unde lin-
ing heimpo anceo pe sonalizedapp oaches oPDdiagnosisand ea men .Fu he 
2 o 9
|
GÓMEZ-GARRE e al.
INTRODUCTION
Pa kinsondisease(PD)isacommonneu odegene a i edisease,
clinically cha ac e ized by h ee ca dinal mo o  symp oms: b a-
dykinesia, es ing emo ,andmuscle igidi y.Howe e ,PDisa
complex,he e ogeneousdiso de wi hab oadspec umo clin-
ical mani es a ions. Beyond mo o  symp oms, PD also p esen s
nume ousnonmo o symp oms,o enappea inglongbe o e he
onse o classicmo o  symp omsandsigni ican ly a ec ing he
quali y o  li e. Demen ia is pa icula ly p e alen , occu ing in
83%o pa ien swi hPD,wi hadiseasedu a iono app oxima ely
20 yea s[1].
The isk o  de eloping PD is de e mined by a complex in e -
playo en i onmen alandgene ic isk ac o s[2], wi h age being
hemos impo an  isk ac o .Theincidenceandp e alenceo PD
inc ease almos  exponen ially wi h age, peaking a  >80 yea s [3].
Likewise,sexisanes ablished isk ac o ,wi hamale/ emale a io
o app oxima ely3:2[1].
Wi hini smul i ac o iale iopa hogenesis,PDis ecognizedas
ahighlycomplexgene icdisease.Nume ouss udiesha ein es i-
ga ed iskandp o ec i e ac o so PD,wi hsigni ican p og essin
gene ic esea chdue o apidad ancesinsequencingme hods.The
gene iccon ibu ion oPDisexplainedbyawidespec umo ge-
ne ic a ian s, anging omcommon a ian s ha con e suscep i-
bili y ode elopingPD,wi hamode a e oweake ec size, o a e
a ian  o ms,highlypene an ,whe e hep esenceo  he a ian 
issu icien  ocause hedisease[4]. To da e, pa hogenic a ian s
associa edwi hmonogenicPDha ebeendesc ibedin>20 genes,
mos o whicha ehighlypene an ando encauseea lyonse o 
a ypicalPD[4].Al houghi hasbeen epo ed ha only5%–10%o 
PDcasesa emonogenic[5], hese da a a e mainly based on indi id-
ualso Eu opean/Whi eances y.The equency,pene ance,and
clinicalimpac o gene ic a ian scan a yac osse hnici ies.Spain
has a complex demog aphic his o y, cha ac e ized by con inuous
occupa ion since ancien imes by a ious popula ions wi h di e se
o igins,includinganeigh -cen u ype iodo A abdomina ion( om
MiddleEas andNo hA ica),wi haclea gene icimpac [6].
This s udy aimed o assess he p esence and con ibu ion o 
a ian sinPD- ela edgenesinacoho o PDpa ien s omsou h-
e nSpain,and oes ablishgeno ype–pheno ypeco ela ions.We
useda a ge ed esequencingpanel, ocusingon27genesassoci-
a edwi hPD,andanalyzed heda ausinganin-housepipeline.Ou 
indingssigni ican lycon ibu e ounde s andingo PD,shedding
ligh on hee ec o gene ic a ian sondiseasede elopmen and
o e ingimpo an insigh sin odiagnosisand ea men o PDinou 
popula ion.
PATIENTS AND METHODS
SeeAppendixS9.
S udy pa icipan s and clinical assessmen s
A o alo 1185PDpa ien swe eincluded om2008.Thediagnoses
we epe o med ollowing heUni edKingdomPa kinson'sDisease
Socie yB ainBankc i e ia[7] o pa ien s ec ui edup o2018and
Mo emen Diso de Socie yclinicaldiagnos icc i e ia[8] om2019
onwa d.
Gene ic analysis
Genomic DNA was isola ed om pe iphe al blood samples om
eachpa icipan .Acombina iono high- esolu ionmel inganalysis,
mul iplexliga ion-dependen p obeampli ica ionanalysis,andnex 
gene a ion sequencing (NGS)-based a ge ed esequencing was
applied(Figu e S1).Va ian swe eca ego izedacco ding o hein-
e na ionalguidelineso  heAme icanCollegeo MedicalGene ics
andGenomics(ACMG)[9](Figu e S2).Only a ian scon o ming o
hegene'sinhe i ancepa e nwe econside edpo en ialdisease-
causing a ian s, and he gene ic diagnosis was conside ed posi i e.
Bioin o ma ics analysis o NGS esul s
All NGS da a we e analyzed employing an in-house pipeline
(AppendixS1).
Tobe e de ine he oleo GBA1 a ian sinPD, a ian sin his
gene we e classi ied using he GBA1-PD b owse  (h ps:// pdgen
e i c s . s h i n y a p p s . i o / G B A 1 B  o w s e / )[10].
Inaddi ion,copynumbe  a ia ions(CNVs)we ealsoanalyzed.
Losseswe ede inedbyamaximumlog2 a ioo −0.55andamini-
mumlog2 a ioo 0.4 o gains[11].
S a is ical analysis
Associa ionanalyseso  he a ian s and PD isk we e pe o med
wi hPLINKso wa e[12].A a e a ian bu denanalysiswascon-
duc edwi hconsis en summa ycoun s-based a e a ian bu den
es [13].Ascon ols,weused wosubcoho s:non-neu oandcon-
olsin heNon-FinnishEu opean-Sou he nEu opean(NFE-SEU)
in es iga ionsin ogene icin e ac ionsandpopula ion-speci ice ec sa ewa an ed o
enhanceou unde s andingo PDe iologyandimp o epa ien ca e.
KEYWORDS
clinicalinsigh s,gene icinsigh s,Pa kinsondisease, a ge edsequencing
14681331, 2025, 1, Downloaded om h ps://onlinelib a y.wiley.com/doi/10.1111/ene.16499 by Readcube (Lab i a Inc.), Wiley Online Lib a y on [14/04/2025]. See he Te ms and Condi ions (h ps://onlinelib a y.wiley.com/ e ms-and-condi ions) on Wiley Online Lib a y o ules o use; OA a icles a e go e ned by he applicable C ea i e Commons License
|
3 o 9
PARKINSON DISEASE IN SPAIN
coho .Wealsousedda a om heCIBERERSpanishVa ian Se e 
(CSVS;h p s : // c s s . c l i n b i o i n o s s p a . e s / )[14].
RESULTS
Demog aphic cha ac e is ics
Weanalyzed27genesassocia edwi hPDinacoho o 1185un-
ela edPDpa ien s(Table 1).Among hem,162(13.7%) epo eda
amilyhis o yo PD,and387(32.7%)hadea lyonse PD(EOPD).The
agea onse (AAO)wasuna ailable o  h eepa ien s,bu  heywe e
classi iedasha ingEOPDbasedon hei cu en age(<50 yea s).
Gene ic spec um
Weiden i ieda o alo 1014 a ian sin hecodingsequenceand
splice egionso  he27analyzedgenes,allwi hamino allele e-
quency(MAF)< 5%in hegene alpopula ion.These a ian swe e
ca ego izedacco ding oACMGc i e iaasbenign(B),likelybenign
(LB), a ian o unknownsigni icance(VUS),likelypa hogenic(LP),
andpa hogenic(P).Among heiden i ied a ian s,898we eloca ed
incoding egionsand116insplice egions(Table S1A and Figu e S3A).
Speci ically,71 a ian swe eclassi iedasP/LP,156asVUS,and788
asB/LB(Table S1B and Figu e S3B).TheP/LP a ian swe e oundin
207pa ien s(17.5%),a ec ing17genes,includingATP13A2, DCTN1,
DNAJC6, FBXO7, LRP10, LRRK2, PRKN, PARK7, PINK1, PLA2G6, POLG,
SMPD1, SPR, SYNJ1, VPS13A, VPS13C, and GBA1. CNVs we e de-
ec ed in he PRKN and SNCAgenes.Conside ing heinhe i ance
pa e no eacha ec edgene,po en iallydisease-causingP/LP a i-
an swe eiden i iedin160pa ien s(13.5%o  hecoho ),in ol -
ing12dis inc genes(DCTN1, DNAJC6, LRP10, LRRK2, PRKN, PINK1,
POLG, SMPD1, SNCA, SPR, VPS13A, and GBA1).Among hese160
pa ien swi hposi i egene icdiagnosis(PGD),se enca iedP/LP
a ian sinmo e hanonegene.Nodisease-causing a ian swe e
iden i iedin960pa ien s(80.9%),whowe econside ed oha ea
nega i egene ic diagnosis (NGD).Addi ionally, 65pa ien s (5.5%;
Figu e 1a and Table S2),we eclassi iedasha inganunknownge-
ne icdiagnosis(UGD),Thisg oupincludedpa ien sca yingVUS,
hose lacking a second a ian in ecessi e genes, and hose wi h
GBA1 a ian sconside edPD isk ac o sacco ding o heGBA1-PD
b owse .Gene icanalysis esul s o eachpa ien a ep o ided in
Table S3.
Va ian sin h eegenes(LRRK2, PRKN, and GBA1)accoun ed o 
72.1%o  heposi i ecases.Themos p e alen genewasLRRK2,
wi h61pa ien s(37.9%)ca yingP/LP a ian s(including49wi h
heG2019S a ian ), ollowedbyPRKN(18%,including12pa ien s
wi h wo a ian sbu wi hou seg ega ionanalysis)andGBA1(18%;
Figu e 1b).
We iden i ied 29 pa ien s (2.45%) ca ying P/LP a ian s in
GBA1. Se e e a ian s we e p esen  in 10 pa ien s (0.84%), mild
a ian sin14pa ien s(1.18%),and unknown a ian sin ou  pa-
ien s. Mo eo e , 21 pa ien s (1.76%) ca ied isk a ian s. Th ee
pa ien s ca ied wo a ian s in GBA1bu didno exhibi symp oms
o  Gauche  disease (GD). The mos  equen  P/LP a ian s we e
p.N409Sandp.L483P,and hemos  equen  a ian was he isk
a ian p.E365K.
Thedis ibu iono pa ien swi hPGD,NGD,o UGDac ossdi -
e en g oupsisshowninFigu e 1c.
Geno ype–pheno ype co ela ions
Pa ien s wi h PGD had a younge  mean AAO (50.6 ± 12.4 yea s)
compa ed o hose wi h NGD (56.7 ± 11.6 yea s) o  UGD
(55.0 ± 12.3 yea s).TheAAO a iedamongdi e en mu a edgenes,
wi hhe e ogenei ye enamongca ie so  a ian sin hesamegene
(Figu e 2).Thep opo iono pa ien swi ha amilyhis o yo PDwas
simila be ween hosewi hPGDandUGD(18.8%and18.5%, e-
spec i ely),andhighe  hanin hosewi hNGD(12.5%;Figu e 3a).A
highe p opo iono women(44.4%)wasno edamongpa ien swi h
PGD,pa icula lyamong hoseca yingP/LP a ian sin heLRRK2
gene(Figu e 3b).
Wealsoexplo ed heassocia ionsbe ween hegeno ypesand
clinical cha ac e is ics in PGD pa ien s (Table S4). Despi e some
missing clinical da a, GBA1PDpa ien sexhibi edahighe p opo -
iono  apideyemo emen sleepbeha io diso de (RBD)andol-
ac o ydys unc ion(88%and68.4%, espec i ely),whe easalowe 
equencyo RBDwasobse edinLRRK2PDpa ien s(39.6%)and
a lowe  equency o  ol ac o y dys unc ion in PRKN PD pa ien s
(6.7%; Table S4). Cogni i e impai men  (CI) was mo e equen 
amongpa ien swi hPGD ela ed oGBA1, DCTN1, POLG, and SPR,
wi hahighe p e alenceinmen(Table 2).
Coho Pa icipan s, nSex, men, n (%)
Age, yea s,
mean ± SD
AAO, yea s,
mean ± SD
Family
PD, n (%)
To al 1185 707(59.7) 64.6 ± 11 55.8 ± 11.9 162(13.7)
EOPD 387 242(62.5) 53.3 ± 9.2 42.5 ± 7.4 53(13.7)
LOPD 798 465(58.3) 69.6 ± 7.8 62.3 ± 7.5 109(13.7)
FamilyPD 162 89(54.9) 65.8 ± 10.2 56.0 ± 12.3 162(100)
Spo adicPD 1023 618(60.4) 64.4 ± 11.1 55.8 ± 11.9 0(0)
Abb e ia ions:AAO,agea onse ;EOPD,ea lyonse PD(agea onse ≤ 50 yea s);LOPD,la eonse 
PD;PD,Pa kinsondisease.
TABLE 1 Demog aphicda ao  hePD
coho .
14681331, 2025, 1, Downloaded om h ps://onlinelib a y.wiley.com/doi/10.1111/ene.16499 by Readcube (Lab i a Inc.), Wiley Online Lib a y on [14/04/2025]. See he Te ms and Condi ions (h ps://onlinelib a y.wiley.com/ e ms-and-condi ions) on Wiley Online Lib a y o ules o use; OA a icles a e go e ned by he applicable C ea i e Commons License
4 o 9
|
GÓMEZ-GARRE e al.
Geno ype–pheno ype co ela ions in well- es ablished
PD- ela ed genes
LRRK2
Dys oniawasobse edin68.4%o LRRK2PDpa ien s,and es ing
emo wasobse edin59.3%.Asubs an ialmajo i yexpe ienced
mo o  luc ua ion(91.8%)anddyskinesias(83.3%),wi hCIandRBD
p esen in31.0%and39.6%, espec i ely. A amilyhis o y o  PD
wasno edonlyamongca ie so  hepa hogenicG2019S a ian 
(Table S4).
In ou coho , LRRK2 PD pa ien s we e p edominan ly women
(60.7%).Thishighe p opo ionwasonlyobse edinca ie so  he
G2019S a ian , among whom 60% we e women. No signi ican 
di e encesinAAOwe eobse edbasedon hespeci ic a ian ca -
ied among LRRK2PDpa ien s,al hough23pa ien s(37.7%)p esen ed
EOPD.Among hese, i epa ien sca iedP/LP a ian sino he genes.
Onepa ien (EP-40)ca iedP/LP a ian sinbo h heLRRK2 and
DCTN1genes,wi hanAAOo 51 yea sandabenigndiseasecou se
wi hou no able nonmo o symp oms.
Twopa ien s(EP-10andEP-16)we e ound oca y heG2019S
a ian andhomozygousPRKN a ian s,exhibi ingclinical ea u es
simila o hose associa ed wi h PRKNPD.
Las ly, wo pa ien s (EP-215 and EP-223) ca ied VUSs and
we e he e o e included in he UGD g oup. Thei  AAOs we e 62
and54 yea s, espec i ely,and heyp esen edwi h es ing emo .
Despi e hei  ela i elyb ie clinical ollow-up, hei clinicaldisease
cou se has been benign.
FIGURE 1 The equencyo causa i e
genes in pa ien s ini ially diagnosed
wi hPa kinsondisease(PD).(a)O e all
diagnos icyield.(b)Dis ibu iono 
disease-causa i egenesin160p obands.
(c)Fea u eso  heanalyzedPDcoho .
EOPD,ea lyonse PD(agea onse 
≤ 50 yea s);LOPD,la eonse PD(age
a onse > 50 yea s);NGD,pa ien s
wi hanega i egene icdiagnosis;PGD,
pa ien s wi h a posi i e gene ic diagnosis;
UGD,pa ien swi hanunknowngene ic
diagnosis.
FIGURE 2 Boxplo so agea onse 
unde speci icgenes.Do s ep esen 
he age a onse in each pa ien ca ying
pu a i e causa i e a ian s in each gene.
Ho izon allines ep esen  hemedian
onse .M,mild;NGD,Pa kinsondisease
(PD)pa ien swi hanega i egene ic
diagnosis;PGD,PDpa ien swi ha
posi i egene icdiagnosis;RF, isk ac o ;
S,se e e;T, o alcoho wi hpa hogenic
o likely pa hogenic a ian s in GBA1 and
hose wi h isk a ian s in GBA1;UGD,
PDpa ien swi hanunknowngene ic
diagnosis.
14681331, 2025, 1, Downloaded om h ps://onlinelib a y.wiley.com/doi/10.1111/ene.16499 by Readcube (Lab i a Inc.), Wiley Online Lib a y on [14/04/2025]. See he Te ms and Condi ions (h ps://onlinelib a y.wiley.com/ e ms-and-condi ions) on Wiley Online Lib a y o ules o use; OA a icles a e go e ned by he applicable C ea i e Commons License
|
5 o 9
PARKINSON DISEASE IN SPAIN
SNCA
Twopa ien s(EP-114andEP-135)ca iedduplica ionso  heen i e
SNCAgeneinhe e ozygosis.Howe e , hecu o poin scouldno 
bede e mined.Onepa ien p esen edwi hala eAAO,whe eas he
o he hadanea lydiseaseonse .Thepa ien wi h heea lie AAO
also ca ied a isk a ian in he GBA1 gene.
PRKN
Al houghmos PRKNPDpa ien sexhibi edanea lyAAOo 
PD,14.3%p esen edla eAAO( anging om55 o59 yea s),
mo o  luc ua ions and dyskinesias we e common (82.1%
and77.8%, espec i ely),andCIandhallucina ions/illusions
we e ela i ely a e(25.9%and18.9%, espec i ely),wi h
FIGURE 3 Ba g aphsshowing amily
his o yo Pa kinsondisease(PD)and
gende dis ibu ionac ossspeci ic
genes.NGD,PDpa ien swi hanega i e
gene icdiagnosis;PGD,PDpa ien s
wi haposi i egene icdiagnosis;UGD,
PDpa ien swi hanunknowngene ic
diagnosis.
TABLE 2 Cogni i eimpai men in heposi i egene icdiagnosiscoho .
LRRK2 PRKN GBA1 GBA1, se e e
GBA1,
mild DCTN1 POLG SMPD1 SPR
n42 27 25 912 3 9 8 8
CI(%) 31.0 25.9 64 55.6 58.3 66.7 66.7 25 62.5
CI-F(%) 33.3 8.3 28.6 25 0 0 66.7 050
CI-M(%) 20 40.0 77.8 80 70 100 66.7 28.6 66.7
D P - C I 15 ± 7.9 16.6 ± 7.8 7.8 ± 6.0 4.8 ± 1.8 11.1 ± 7.7 7.5 ± 3.5 10.0 ± 5.0 7.5 ± 3.5 9.4 ± 2.9
D P - C I - F 15.8 ± 6.9 15 4.5 ± 3.5 2 0 0 11.5 ± 6.4 010
D P - C I - M 16.5 ± 13.4 16.8 ± 8.5 8.2 ± 6.3 5.1 ± 1.0 11.1 ± 7.7 7.5 ± 3.5 9.3 ± 5.1 7.5 ± 3.5 9.3 ± 3.3
No e:Thede elopmen o CIwasconside ed h oughou  he ollow-up.Themean ollow-up imewas15.1 ± 8.5 yea s.
Abb e ia ions:CI,cogni i eimpai men ;CI(%),pe cen ageo PGD-pa ien swi hCI;CI-F(%),pe cen ageo womenwi hPGDandCI;CI-M(%),pe cen age
o menwi hPGDandCI;DP-CI,diseasep og ession oCI(meano yea s ± SD);DP-CI-F,diseasep og ession oCI(meano yea s ± SD)inwomen;DP-
CI-M,diseasep og ession oCI(meano yea s ± SD)inmen;n,sampleswi hposi i egene icdiagnosis(PGD)andCIda a;PGD,posi i egene icdiagnosis.
14681331, 2025, 1, Downloaded om h ps://onlinelib a y.wiley.com/doi/10.1111/ene.16499 by Readcube (Lab i a Inc.), Wiley Online Lib a y on [14/04/2025]. See he Te ms and Condi ions (h ps://onlinelib a y.wiley.com/ e ms-and-condi ions) on Wiley Online Lib a y o ules o use; OA a icles a e go e ned by he applicable C ea i e Commons License

6 o 9
|
GÓMEZ-GARRE e al.
CI mo e p e alen  among men (40%) han women (8.3%;
Table 2).
PINK1
Onepa ien (EP-3)ca iedLPmissense a ian sinpu a i ecompound
he e ozygosi yin hePINK1gene.Thispa ien p esen edwi hea lyAAO
(49 yea s),mo o  luc ua ions,dyskinesias,and dys onia.Addi ionally,
al houghCIwasno p esen ,hallucina ions/illusionsoccu ed.
GBA1
Wede ec ed13di e en  a ian sin heGBA1gene.Acco ding o
hei e ec onGDandPD, i ewe edesc ibedasse e e, h eeas
mild,and woas isk a ian s, hei  equencybeing4.9%inEOPD
and3.1%inla eonse PD.TheAAOo  hoseca ying he isk a i-
an sp.E365Kandp.T408Mwasla e  han he es .
Mo o  luc ua ionsanddyskinesiaswe emo e equen inpa-
ien s wi h mild a ian s compa ed wi h hose wi h se e e a ian s
(61.5% s.50%,and69.2% s.66.7%, espec i ely).Al hough1pa-
ien (EP-105)p esen edwi h wose e e a ian sinGBA1, no signs
o  GD ha e been epo ed in his clinical his o y, sugges ing ha 
hose a ian s a e p obably in cis.
RBD and ol ac o y dys unc ion we e obse ed wi h highe 
equency in pa ien s ca ying se e e a ian s (87.5% and 71.4%,
espec i ely) compa ed wi h hose wi h mild a ian s (84.6% and
66.7%, espec i ely).
CIwasp esen inapp oxima elyhal o  heGBA1pa ien s(a -
ec ingahighe p opo iono malepa ien s),anddiseasep og es-
sion oCIwaslowe in hepa ien sca yingGBA1 se e e a ian s
compa ed wi h hose wi h GBA1mild a ian s(Table 2).
Geno ype–pheno ype in genes linked wi h
pa kinsonism wi h a ypical signs
DCTN1
Sixpa ien s(0.5%o  hePDcoho )ha bo edanLP a ian in he
DCTN1 gene: c.414 + 1G > A ( s576198476). This a ian  displayed
acombined anno a ion dependen  deple ion(CADD) alueo  33
andwasdesc ibedasLPacco ding oACMGc i e ia.Inou popula-
ion, DCTN1PDpa ien sp esen edameanAAOo 59.5 ± 6.9 yea s
(Figu e 2),good esponse ole odopa,andmo o  luc ua ionsand
dyskinesia.Mos o  hesepa ien sexpe iencedpa icula lyse e e
neu opsychia icsymp oms,and he e o e heydidno  ole a ehigh
doseso dopamine gicmedica ion.O he  ea u es,suchas espi a-
o y symp oms and weigh loss, we e absen in hei clinical his o y.
Addi ionally,onepa ien ca iedbo h heDCTN1c.414 + 1G > A a i-
an and he LRRK2G2019S a ian ,showinganea lie AAOanda
lacko neu opsychia icsymp oms.
DNAJC6
Onepa ien (EP-47)wi hala eAAOha bo ed woLP a ian sin
DNAJC6, p esen ing wi h a ypical PD pheno ype. Bo h a ian s
we e ameshi  changes likely in compound he e ozygosi y bu 
wi hou bialleliccon i ma ion.
LRP10
Onepa ien (EP-29)wi hno amilyhis o yo PDca iedanon-
sense a ian in he LRP10gene.Thispa ien p esen edala eAAO
andde elopedCIandhallucina ions/illusions5 yea sa e disease
onse .
POLG
Se en di e en  P/LP a ian s we e iden i ied in 11 pa-
ien s wi h a wide ange o  AAOs. I  is known ha  wo
o  hese a ian s(p.Th 251Ileandp.P o587Leu)a elinked
andin cis. The e o e,all POLG pa ien s we e conside ed
monoallelic.
Mo o  luc ua ionswe ep esen in81.8%o  hePOLGPDpa-
ien s. Dyskinesias, CI, RBD, and ol ac o y dys unc ion we e also
equen lyobse ed(70%,80%,70%,and71.4%, espec i ely).No
pa ien wasspeci icallydesc ibedasha inga axiao pe iphe alneu-
opa hy.Onepa ien (EP-54)p esen edp og essi eex e naloph-
halmoplegia(PEO).
SMPD1
Ele endi e en P/LP a ian sinSMPD1we ede ec edin15PDpa-
ien s,who equen lyexhibi edmo o  luc ua ionsandRBD(71.4%
and75%, espec i ely).Dyskinesias(61.5%)andhyposmia(62.5%)
we e also common, al hough hallucina ions/illusions we e a ely e-
po ed(23.1%).
SPR
AnLP a ian (p.Asp69Glu;c.207C > G)in heSPR gene was de ec ed
ineigh pa ien swi hPD.Mo o  luc ua ionsanddyskinesiaswe e
highly p e alen in SPRPDpa ien s(87.5%and75%, espec i ely);
howe e ,dys oniawasobse edin50%.OnlyoneSPRPDpa ien 
epo eda amilyhis o yo PD.
VPS13A
Onepa ien ca iedanLP a ian inVPS13A;howe e ,clinicalin o -
ma ion o  hisindi idualisuna ailable.
14681331, 2025, 1, Downloaded om h ps://onlinelib a y.wiley.com/doi/10.1111/ene.16499 by Readcube (Lab i a Inc.), Wiley Online Lib a y on [14/04/2025]. See he Te ms and Condi ions (h ps://onlinelib a y.wiley.com/ e ms-and-condi ions) on Wiley Online Lib a y o ules o use; OA a icles a e go e ned by he applicable C ea i e Commons License
|
7 o 9
PARKINSON DISEASE IN SPAIN
Gene bu den analysis
Asigni ican associa ionwi h e y a e a ian swas ound o  he
DNAJC13 gene, and PRKNshowedasimila pa e nin hecon ex o 
loss-o - unc ion a ian swi haCADD> 25.Fu he mo e,PLA2G6
and POLG showed associa ions wi hnoncommonloss-o - unc ion
a ian s(Table S5).
DISCUSSION
This s udyaimed ode ine heclinicalspec um and implica ions
o gene ic a ian sac oss27genesinaPDpopula ion omsou h-
e nSpain.Ou  indings e ealedasigni ican gene iche e ogene-
i y,wi hpo en iallycausa i eP/LP a ian siden i iedin12genes
(DCTN1, DNAJC6, LRP10, LRRK2, PRKN, PINK1, POLG, SMPD1, SNCA,
SPR, VPS13A, and GBA1).
The analysis o  ypical and a ypical o ms o  monogenic PD
e ealed se e al no able di e ences. Pa ien s wi h a ypical
o msexhibi edahighe AAOanda educed amilyhis o yo PD.
Fu he mo e,weobse edsex-speci icdi e encesin hep e alence
o P/LP a ian s,pa icula lyin heLRRK2gene.Ahighe p opo ion
o womenwe e ound oca yLRRK2 a ian s, d i en pa icula ly
by heG2019S a ian (wi h60%o  heca ie sbeingwomen)bu 
no amongca ie so o he LRRK2 a ian s.This indingalignswi h
p e iouss udiesindica inga emalep edominanceamongG2019S
a ian ca ie s[15].Al hougho he s udiesha eno  epo ed his
gende e ec [16],ala geme a-analysisin2018o LRRK2- ela ed
clinical ea u es epo ed a simila  emale p edominance among
G2019Sca ie s[17].
LRRK2 eme ged as he mos p e alen gene, wi h a no able
p opo iono pa ien sca ying heG2019S a ian (4%o cases),
simila  oo he Eu opeans[18] bu sligh ly highe han ha e-
po edin heb oade Spanishpopula ion[19].Clinically,LRRK2-
associa edPDpa ien sexhibi ed ea u essimila  o hosewi h
spo adicPD.Howe e , he ela i elylowe p e alenceo CIand
RBDsugges spo en ialdi e encesindiseasep og essionand
unde lyingneu opa hology.Theiden i ica iono a amilyhis o y
o PDexclusi elyamongca ie so  heG2019S a ian unde -
sco es he ele anceo speci icgene ic a ian sin amilial o ms
o PDandemphasizes heimpo anceo gene iccounseling[20,
21].
Inlinewi ho he s udies,ou coho showsahighe  equency
o  he dele e ious p.Asn52 s a ian  in PRKN compa ed o o he
popula ions. This a ian has been ela ed wi h an in onic signal in
PRKN,desc ibedasanAAOmodi ie ,highligh ing heimpo anceo 
s udying di e se popula ions o be e unde s and he gene ic con-
ibu ions oPD[19].
In e es ingly,nosigni ican di e encesinAAOwe eobse ed
among LRRK2 a ian ca ie s, al hough some pa ien s wi h LRRK2
and PRKN a ian sp esen edwi hAAOsou side he ypical ange.
This ein o ces heno ion ha addi ionalgene icanden i onmen al
ac o slikelymodula ediseasep esen a ion.
Mo eo e ,CIwaslesscommonand ended oappea la e inpa-
ien swi hPGDassocia edwi hLRRK2 o PRKN compa ed o hose
wi hPGDassocia edwi ho he genes,suchasGBA1, DCTN1, POLG,
and SPR.
Al houghPINK1-associa edPDhasbeen epo edas hesecond
mos commoncauseo au osomal- ecessi ePD,i was e y a ein
ou coho .
Twopa ien swe e ound oca yduplica ionsin heSNCA gene;
howe e , hep eciseb eakpoin so  heseduplica ionscouldno be
de e mina ed.In e es ingly,oneo  hesepa ien salsoca ied he
p.T408M isk a ian inGBA1andhadamuchea lie AAO(38 s.
61 yea s),sugges ing ha gene icin e ac ionsbe ween hesegenes
mayin luencediseasecou se.
Va ian sin heGBA1geneha ebeenclassi iedacco ding o hei 
e ec onGDandPD[10, 22].Con a y op e ious indings[23], ou
s udy ound ha pa ien sca yingmildGBA1 a ian s had an ea lie
AAOcompa ed o hosewi hse e e a ian s.Addi ionally, wopa-
ien sca yingbo hase e e a ian anda isk a ian (wi hou e i-
denceo GD)p esen edwi hala e AAO,sugges inganin e ac ion
be ween hese wo a ian s.
Va ian singenesassocia edwi ha ypicalpa kinsonism,suchas
LRP10, DCTN1, DNAJC6, POLG, SPR, and SMPD1, we e linked o dis-
inc clinical p esen a ions and disease cou ses, highligh ing he im-
po anceo conside inggene ic ac o sin hedi e en ialdiagnosis
o pa kinsoniansynd omes.
The e o e, al hough mu a ions in POLG gene, inhe i ed in an
au osomaldominan o  ecessi emanne ,ha ebeenlinked oPEO
[24],inou coho onlyonepa ien exhibi edi ,ca ying hep.Ty -
955Cys a ia ion,whichhasbeenp e iouslyassocia edwi hPEO
[24]. This sugges s a geno ype–pheno ype co ela ion.
The LRP10genehasbeenp oposedascausa i einau osomal-
dominan PD,wi ho wi hou demen ia[25, 26]. One pa ien in ou
coho p esen ed clinical cha ac e is ics consis en wi h LRP10-
ela ed PD,al hough he absenceo a amilyhis o yo PD could
sugges lowpene ance o  his a ian .
DCTN1gene a ian sha ebeenlinked oPe ysynd ome(PS)
[27], a a eau osomal-dominan  adul onse  neu odegene a i e
diso de cha ac e izedbya ypicalpa kinsonism,dep ession/apa-
hy,weigh loss,and espi a o ysymp oms[28].Pa hogenicmu a-
ionsinPSa e ypically oundwi hin hecy oskele on-associa ed
p o ein glycine- ich(CAP-Gly) domain[29].Howe e ,ou s udy
iden i ied hec.414 + 1G > A a ian ou side hisdomain.Al hough
ca ie so  his a ian we eclassi iedasha ingaPGD, he e e-
mains unce ain y abou  i s ac ual in ol emen  in PD de elop-
men .This a ian wasalsop esen inheal hycon ols om he
CSVSpopula ion(MAF = 0.0019),al houghwi hsligh lylowe  e-
quencycompa edwi hou PDpopula ion(MAF = 0.0025).Thus,
mo ee idenceisneeded ocon i mi spa hogenici y.Ou  indings
sugges ha a ian s in he DCTN1geneou side heCAP-Glydo-
maincouldha euniqueimplica ionsinPD,possiblyp esen inga
isk ac o .
Homozygous a ian sinDNAJC6ha ebeenlinked oau osomal-
ecessi eea lyonse PD.Inou coho ,onepa ien ca ied woLP
14681331, 2025, 1, Downloaded om h ps://onlinelib a y.wiley.com/doi/10.1111/ene.16499 by Readcube (Lab i a Inc.), Wiley Online Lib a y on [14/04/2025]. See he Te ms and Condi ions (h ps://onlinelib a y.wiley.com/ e ms-and-condi ions) on Wiley Online Lib a y o ules o use; OA a icles a e go e ned by he applicable C ea i e Commons License
8 o 9
|
GÓMEZ-GARRE e al.
a ian s,wi hala e AAO hanp e iously epo ed.Addi ional es s
a e equi ed ocon i m hei causali y.
Eigh indi idualsca iedanLP a ian (p.Asp69Glu;c.207C > G)
in he SPR gene, sugges ing a ounde  e ec  in ou  coho . A
popula ion-speci ic ole o  hisgenehasbeensugges ed[30]. The
SPR gene encodes sepiap e in educ ase, a key p o ein in e ahyd-
obiop e in(BH4)syn hesis,aco ac o c i icalin hesyn hesisand
sec e iono neu o ansmi e ssuchasdopamine.BH4 de iciency
hasbeenassocia edwi hcondi ionscha ac e izedbymo emen dis-
o de sandmen al e a da ion,amongo he s[31].Howe e , he e
iscon lic inge idence ega ding he oleo SPRinPDpa hogenesis
[31].Desc ibedasaVUSinClinVa , he a ian c.207C > Ghasbeen
p e iously associa ed wi h au osomal-dominan  dopa- esponsi e
dys onia[32].Inou coho ,62%o SPRpa ien sp esen edwi hCI,
andonly50%p esen edwi hdys onia,sugges ing ha  his a ian 
maybeaPD isk ac o inou popula ion.
He e ozygous a ian sinSMPD1(encodingacidsphingomyelin-
ase)ha ebeeniden i iedas isk ac o s o PD[33]. In ou coho ,
1.26%o pa ien sca iedP/LP a ian sinSMPD1, suppo ing i s ole
inPD.No ably,hal o  hesepa ien sexhibi edRBD,unde sco ing
heclinicalimpo anceo  hisgene.
Ac ually,i isc i ical oinc easeou knowledgeo gene ic isks
o  PD in indi iduals o  a ied gene ic backg ounds and inc ease
hea ailabili yo de ailedclinalda aassocia edwi h hem.In his
con ex ,s udyingou PDpopula ion oma egionwi hhis o ically
uniquedemog aphiccha ac e is icsinEu opeadds aluableda a o
ou unde s andingo PDpa hogenesis.
Toou knowledge, hisis hela ges s udyo PD oda econ-
duc edinsou he nSpain,p o idingin o ma ionin o hegene ic
a ian s and hei  associa ed clinical ea u es. Howe e , we ac-
knowledge se e al limi a ions, including he inabili y o es ablish a
clea geno ype–pheno ypeco ela ion o somegenesdue o he
limi edsizeo  hesampleswi hPGD,a ec ing hosegenesand
challenges ela ed omissingclinicalda a.Inaddi ion, heuseo a
a ge edgenepanel es ic edou abili y oanalyze ecen lydis-
co e ed genes such as RAB32[34]. Finally, i is impo an o no e
ha  he ela i elylow equencyo GBA1 pa hogenic a ian s in
ou popula ion could be due o echnical challenges ela ed o he
exis enceo ahighlysimila pseudogene.Thismayha eled oan
unde es ima ion o  he ue p e alenceo GBA1 a ian sinPD
pa ien s.
Despi e hese limi a ions, ou s udy p o ides impo an insigh s
in o hegene icbasiso PDandi sclinicalmani es a ions.Theob-
se ed geno ype–pheno ype co ela ions and sex-speci ic di e -
enceshighligh  heimpo anceo pe sonalizedapp oaches oPD
diagnosis and ea men .
CONCLUSIONS
Ou  esul shighligh  hecomplexi yo gene iccon ibu ions oPD
pheno ype and p ognosis. Comp ehensi e gene ic p o iling and
pe sonalized isks a i ica iona ec ucial o guidingp ognosisand
he apeu ic decision-making in PD pa ien s. The e a e nume ous
mechanismsassocia edwi hPDpa hogenesisandp og ession ha 
lead oPD.Fu he in es iga ionsin ogene icin e ac ionsand he
inclusiono  amilyhis o yandsex-speci icda awillbekey obe e 
unde s andingPDpa hogenesis.
AUTHOR CONTRIBUTIONS
Pila Gómez- Ga e:Concep ualiza ion;supe ision; o malanalysis;
undingacquisi ion;p ojec adminis a ion;w i ing–o iginald a ;
w i ing – e iew and edi ing. Miguel Ma ín- Bó nez: Da a cu a ion;
o malanalysis;me hodology;so wa e;w i ing– e iewandedi -
ing. Lau a Muñoz- Delgado: Da a cu a ion; in es iga ion; esou ces;
w i ing – e iew and edi ing. Ra ael Díaz- Belloso: Fo mal analysis;
in es iga ion; w i ing – e iew and edi ing. Ma ía Te esa Pe iñán:
Fo mal analysis; in es iga ion; w i ing – e iew and edi ing. Ma a
Bonilla- To ibio: Me hodology; w i ing – e iew and edi ing. Dolo es
Buiza- Rueda: Me hodology; w i ing – e iew and edi ing. Daniel
Macías- Ga cía: Resou ces; w i ing – e iew and edi ing. Sil ia Jesús:
Resou ces; w i ing – e iew and edi ing. As id Ada mes- Gómez:
Resou ces; w i ing – e iew and edi ing. Elena Ojeda: Resou ces;
w i ing – e iew and edi ing. An onio Luque- Amb osiani: Resou ces;
w i ing – e iew and edi ing. Se gio Ga cía- Díaz:W i ing– e iew
and edi ing. Rocío Pineda Sánchez: Me hodology. Fá ima Ca illo:
Resou ces. Pablo Mi : Concep ualiza ion; supe ision; unding
acquisi ion; p ojec  adminis a ion; w i ing – e iew and edi ing;
esou ces.
ACKNOWLEDGMENTS
Theau ho swouldlike o hank hedono s, heUni e si yHospi al
Vi gen del Rocio, and he Biomedical Ins i u e o  Se ille Biobank
(Andalusian Public Heal h Sys em Biobank and ISCIII-Red de
BiobancosPT20/00069) o  hehumanspecimensusedin hiss udy.
FUNDING INFORMATION
Thiswo kwassuppo edby heSpanish Minis yo Scienceand
Inno a ion (RTC2019-007150-1); he Ins i u o de Salud Ca los III
(ISCIII)co undedby heEu opeanUnion(PI14/01823,PI16/01575,
PI18/01898,PI19/01576,PI21/01875); heConseje íadeEconomía,
Inno ación,CienciayEmpleodelaJun adeAndalucía(CVI-02526,
CTS-7685,PY20_00896);and heConseje íadeSaludyBienes a 
SocialdelaJun adeAndalucía(PI-0471-2013,PE-0210-2018,PI-
0459-2018,PE-0186-2019).P.G.-G.wassuppo edby heNicolás
Mona desp og am(C-0048-2017)o AndalusianRegionalMinis y
o  Heal h. D.M.-G. was suppo ed by he Juan Rodés p og am
(JR22/00073) o  ISCIII co unded by he Eu opean Union FSE+
(ISCIII-FEDER).L.M.-D.wassuppo edby heRíoHo egap og am
(CM21/00051) o  ISCII co unded by he Eu opean Union FSE+
(ISCIII-FEDER).The unde shadno olein hes udydesign,da a
collec ion and analysis, decision o publish, o  p epa a ion o  he
manusc ip .
CONFLICT OF INTEREST STATEMENT
Theau ho sdecla enocon lic o in e es .
14681331, 2025, 1, Downloaded om h ps://onlinelib a y.wiley.com/doi/10.1111/ene.16499 by Readcube (Lab i a Inc.), Wiley Online Lib a y on [14/04/2025]. See he Te ms and Condi ions (h ps://onlinelib a y.wiley.com/ e ms-and-condi ions) on Wiley Online Lib a y o ules o use; OA a icles a e go e ned by he applicable C ea i e Commons License
|
9 o 9
PARKINSON DISEASE IN SPAIN
DATA AVAILABILITY STATEMENT
Theda a ha suppo  he indingso  hiss udya ea ailablein he
supplemen a yma e ialo  hisa icle.
ORCID
Pila Gómez- Ga e h ps://o cid.o g/0000-0002-0437-6182
Miguel Ma ín- Bó nez h ps://o cid.o g/0000-0001-8221-3816
Ra ael Díaz- Belloso h ps://o cid.o g/0000-0003-4713-9248
Daniel Macías- Ga cía h ps://o cid.o g/0000-0002-4822-1529
Pablo Mi h ps://o cid.o g/0000-0003-1656-302X
REFERENCES
 1. Kalia LV, Lang AE. Pa kinson's disease. Lance .
2015;386(9996):896-912.
 2. PangSY,HoPW,LiuHF,e al.Thein e playo aging,gene icsand
en i onmen al ac o sin hepa hogenesiso Pa kinson'sdisease.
T ansl Neu odegene .2019;8:23.
 3. D i e  JA, Log oscino G, Gaziano JM, Ku h T. Incidence and
emaining li e ime isk o  Pa kinson disease in ad anced age.
Neu ology.2009;72(5):432-438.
 4. Blauwend aa C,NallsMA,Single onAB.Thegene ica chi ec u e
o Pa kinson'sdisease.Lance Neu ol.2020;19(2):170-178.
 5. Luna iA,LesageS,B iceA.Thegene iclandscapeo Pa kinson's
disease. Re Neu ol (Pa is).2018;174(9):628-643.
 6. Byc o C,Fe nandez-RozadillaC,Ruiz-Pon eC,e al.Pa e nso 
gene icdi e en ia ionand he oo p in so his o icalmig a ionsin
heIbe ianPeninsula.Na Commun.2019;10(1):551.
 7. GibbWR,LeesAJ.The ele anceo  heLewybody o hepa ho-
genesis o  idiopa hic Pa kinson's disease. J Neu ol Neu osu g
Psychia y.1988;51(6):745-752.
 8. Pos umaRB,Be gD,S e nM,e al.MDSclinicaldiagnos icc i e ia
o Pa kinson'sdisease.Mo Diso d.2015;30(12):1591-1601.
 9. Richa dsS,AzizN,BaleS,e al.S anda dsandguidelines o  he
in e p e a ion o  sequence a ian s: a join  consensus ecom-
menda ion o  he Ame ican College o  Medical Gene ics and
Genomicsand heAssocia ion o Molecula Pa hology.Gene Med.
2015;17(5):405-424.
10. Pa la  SC, G enn FP, Kim JJ, Baluwend aa  C, Gan-O  Z.
Classi ica iono GBA1 a ian sinPa kinson'sdisease: heGBA1- P D 
B owse .Mo Diso d.2023;38(3):489-495.
11. PughTJ,Am SS,Bowse MJ,e al.VisCap:in e enceand isual-
iza ion o  ge m-line copy-numbe  a ian s om a ge ed clinical
sequencingda a.Gene Med.2016;18(7):712-719.
12. Pu cellS,NealeB,Todd-B ownK,e al.PLINK:a oolse  o whole-
genomeassocia ionandpopula ion-basedlinkageanalyses.Am J
Hum Gene .2007;81(3):559-575.
13. ChenW,WangS,Ti hiSS,EllisonDW,SchaidDJ,WuG.A a e a ian 
analysis amewo kusingpublicgeno ypesumma ycoun s op io i-
izedisease-p edisposi iongenes.Na Commun.2022;13(1):2592.
14. Pena-Chile  M, Roldan G, Pe ez-Flo ido J, e  al. CSVS, a c owd-
sou cing da abase o  he Spanish popula ion gene ic a iabili y.
Nucleic Acids Res.2021;49(D1):D1130-D1137.
15. O -U ege A,Shi inC,Rozo skiU,e al.TheLRRK2G2019Smu-
a ioninAshkenaziJewswi hPa kinsondisease:is he eagende 
e ec ?Neu ology.2007;69(16):1595-1602.
16. Gan-O  Z, Leblond CS, Malle  V, O -U ege  A, Dion PA,
Rouleau GA. LRRK2mu a ionsinPa kinsondisease;asexe -
ec  o  lack he eo ? A me a-analysis. Pa kinsonism Rela Diso d.
2015;21(7):778-782.
17. ShuL,ZhangY,PanH,e al.Clinicalhe e ogenei yamongLRRK2
a ian s in Pa kinson's disease: a me a-analysis. F on Aging
Neu osci.2018;10:283.
18. Healy DG, Falchi M, O'Sulli an SS, e  al. Pheno ype, geno-
ype,andwo ldwidegene icpene anceo LRRK2-associa ed
Pa kinson's disease: a case–con ol s udy. Lance Neu ol.
2008;7(7):583-590.
19. Band es-CigaS,AhmedS,Sabi MS,e al.Thegene ica chi ec u e
o  Pa kinson disease in Spain: cha ac e izing popula ion-speci ic
isk,di e en ialhaplo ypes uc u es,andp o idinge iologicin-
sigh . Mo Diso d.2019;34(12):1851-1863.
20. TaymansJM,FellM,G eenamy eT,e al.Pe spec i eon hecu -
en s a eo  heLRRK2 ield.NPJ Pa kinsons Dis.2023;9(1):104.
21. RochaEM,KeeneyMT,DiMaioR,DeMi andaBR,G eenamy e
JT. LRRK2 and idiopa hic Pa kinson's disease. T ends Neu osci.
2022;45(3):224-236.
22. S i nemannJ,Belma ougN,CamouF,e al.A e iewo Gauche 
disease pa hophysiology, clinical p esen a ion and ea men s. In J
Mol Sci.2017;18(2):441.
23. Gan-O  Z, Amshalom I, Kila ski LL, e  al. Di e en ial e ec s o 
se e e s. mild GBA mu a ions on Pa kinson disease. Neu ology.
2015;84(9):880-887.
24. DaPozzoP,Ca daioliE,RubegniA,e al.No elPOLG mu a ions
and a iable clinical pheno ypes in 13 I alian pa ien s. Neu ol Sci.
2017;38(4):563-570.
25. Quad i M, Mandemake s W, G ochowska MM, e  al. LRP10 ge-
ne ic a ian s in amilial Pa kinson's disease and demen ia wi h
Lewybodies:agenome-widelinkageandsequencings udy.Lance
Neu ol.2018;17(7):597-608.
26. ManiniA,S anie oL,Mon iniE,e al.Sc eeningo LRP10 mu a-
ionsinPa kinson'sdiseasepa ien s omI aly.Pa kinsonism Rela
Diso d.2021;89:17-21.
27. Fa e MJ,HulihanMM,Kache gusJM,e al.DCTN1 mu a ions in
Pe ysynd ome.Na Gene .2009;41(2):163-165.
28. Mishima T, Fujioka S, Tomiyama H, e  al. Es ablishing diagnos-
ic c i e ia o  Pe y synd ome. J Neu ol Neu osu g Psychia y.
2018;89(5):482-487.
29. DulskiJ,KogaS,Libe ski PP,e al.Pe ydisease:expanding he
gene ic basis. Mo Diso d Clin P ac .2023;10(7):1136-1142.
30. Sha maM,Ma agano eDM,IoannidisJP,e al.Roleo sepiap e in
educ asegenea  hePARK3locusinPa kinson'sdisease.Neu obiol
Aging.2011;32(11):2108.
31. WuY,ChenP,SunL,e al.Sepiap e in educ ase:cha ac e is ics
and ole in diseases. J Cell Mol Med.2020;24(17):9495-9506.
32. ShalashAS,Rosle TW,Mulle SH,e al.c.207C>Gmu a ionin
sepiap e in educ asecausesau osomaldominan dopa- esponsi e
dys onia. Neu ol Gene .2017;3(6):e197.
33. Alcalay RN, Malle  V, Vande pe e B, e  al. SMPD1 mu a ions,
ac i i y,andalpha-synucleinaccumula ioninPa kinson'sdisease.
Mo Diso d.2019;34(4):526-535.
34. Gus a ssonEK,Folle J,T inhJ,e al.RAB32Se 71A ginau oso-
maldominan Pa kinson'sdisease:linkage,associa ion,and unc-
ional analyses. Lance Neu ol.2024;23:603-614.
SUPPORTING INFORMATION
Addi ional suppo ing in o ma ion can be ound online in he
Suppo ingIn o ma ionsec iona  heendo  hisa icle.
How o ci e his a icle: Gómez-Ga eP,Ma ín-Bó nezM,
Muñoz-DelgadoL,e al.Unde s andingPa kinsondiseasein
Spain:Gene icandclinicalinsigh s.Eu J Neu ol.
2025;32:e16499. doi:10.1111/ene.16499
14681331, 2025, 1, Downloaded om h ps://onlinelib a y.wiley.com/doi/10.1111/ene.16499 by Readcube (Lab i a Inc.), Wiley Online Lib a y on [14/04/2025]. See he Te ms and Condi ions (h ps://onlinelib a y.wiley.com/ e ms-and-condi ions) on Wiley Online Lib a y o ules o use; OA a icles a e go e ned by he applicable C ea i e Commons License